The immune system is built to communicate.
Our mission is to listen.
We apply machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights. MeMed’s AI-based diagnostics address key clinical and medical challenges in infectious diseases and inflammatory disorders.
Because bacterial and viral infections are often indistinguishable, clinicians struggle to answer the question, ‘Do I need to treat with antibiotics or not?’ MeMed BV® is the first FDA-cleared host-immune response assay for accurately distinguishing between bacterial and viral infections in just 15 minutes.
MeMed Key® is a cutting edge, compact immunoassay platform that makes it possible to conduct highly sensitive, rapid, multiplexed protein measurements that previously could only be done on large, expensive central lab equipment.
Together, MeMed Key and MeMed BV help physicians enhance patient management and make better informed antibiotic treatment decisions.
MeMed BV and MeMed Key performance was validated in multi-national, double-blind clinical studies and real world use in >20,000 patients.
External Double-Blind Prospective Validation
Our unique emphasis on quality and breadth of clinical evidence sets MeMed apart. MeMed BV performance has been validated in multi-national, double-blind clinical studies and real world real world settings enrolling over 20,000 subjects in Europe, Israel and the United States.1-7 These studies have consistently demonstrated compelling performance results in different clinical settings, age groups, and patients with different clinical syndromes.
Additional Clinical Dilemmas
By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas like infection severity and others.
- MeMed data on file. Apollo Clinical Study (NCT04690569) conducted to establish the diagnostic performance of the MeMed BV Test for differentiating bacterial from viral infection in patients with suspected acute bacterial or viral infection.
- Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PloS one. 2015 Mar 18;10(3):e0120012.
- van Houten CB, de Groot JA, Klein A, Srugo I, Chistyakov I, de Waal W, et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): A double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr 1;17(4):431-40.
- Srugo I, Klein A, Stein M, Golan-Shany O, Kerem N, Chistyakov I, et al. Validation of a novel assay to distinguish bacterial and viral infections. Pediatrics. 2017 Oct 1;140(4).
- Ashkenazi-Hoffnung L, Oved K, Navon R, Friedman T, Boico O, Paz M, et al. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: A prospective observational study. Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1361-71.
- Stein M, Lipman-Arens S, Oved K, Cohen A, Bamberger E, Navon R, et al. A novel host-protein assay outperforms routine parameters for distinguishing between bacterial and viral lower respiratory tract infections. Diagn Microbiol Infect Dis. 2018 Mar 1;90(3):206-13.
- Eden E, Srugo I, Gottlieb T, Navon R, Boico O, Cohen A, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. J Infect. 2016 Aug 1;73(2):177-80.